BOSENTAN - AN OVERVIEW

six The phosphodiesterase-five inhibitor sildenafil is accredited for PAH in FC I–IV from the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) such as bosentan, sitaxentan and ambrisentan are oral therapies accredited for use in PAH. As no oral agent has proven superiority there remains discussion regarding which mu